The objective of the present study was to assess the sub-chronic effect of combination between ethephon and gibberellic acid on brain mitochondrial adenosine tri-phosphatas, brain and whole blood acetyl cholinesterase. Male ICR (CD-1) mouse was used as an experimental model. The experiment duration was 23 weeks through which animals received diets containing ethephon in a series of concentrations of 0, 25, 50 and 75 milligram per kilogram diet respectively with and without 50 mg of gibberellic acid. A significant variation was recorded between the effect of ethephon and that of ethephon -gibberellic acid combination on the activity of total mitochondrial ATPase in mice brain (P ≤ 0.05). Gibberellic acid antagonized the inhibition occurred by ethephon in case of the two smaller dietary concentrations 25 and 50 mg / kg diet. Ethephon induced a highly significant (p ≤ 0.01) concentrationdependent activation in Mg +2 ATPase in animals exposed to the two lower dietary concentrations 25 and 50 mg / kg with and without gibberellic acid. Ethephon induced a highly significant (p ≤ 0.01) dietary concentration-dependent inhibition in brain Na + / K + ATPase. Gibberellic acid obviously reduced inhibition in animals received the two smaller concentrations (25 and 50 mg / kg diet). No significant variation was found in brain acetyl cholinesterase neither among treated groups nor between these groups and the control (p ≥ 0.05). Gibberellic acid induced a highly significant recovery in the inhibited whole blood AChE in groups fed the low concentrations of 25 and 50 mg / kg diet (p ≤ 0.01). While at higher concentration (75 mg / kg diet) gibberellic acid showed an additive inhibitory effect on whole blood AChE.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.